147 related articles for article (PubMed ID: 8500111)
1. IgM monoclonal antibody JD118 recognizes an inducible antigen target for human-complement-mediated cytotoxicity against neoplastic B cells.
Czuczman MS; Garin-Chesa P; Lemoli RM; Scheinberg DA
Cancer Immunol Immunother; 1993 Jun; 36(6):387-96. PubMed ID: 8500111
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-4 priming enhances a target for human complement-mediated cytotoxicity of CLL.
Czuczman MS; Class K; Scheinberg DA
Leukemia; 1993 Jul; 7(7):1020-5. PubMed ID: 7686603
[TBL] [Abstract][Full Text] [Related]
3. Elimination of clonogenic tumor cells from human bone marrow using a combination of monoclonal antibody:ricin A chain conjugates.
Bregni M; De Fabritiis P; Raso V; Greenberger J; Lipton J; Nadler L; Rothstein L; Ritz J; Bast RC
Cancer Res; 1986 Mar; 46(3):1208-13. PubMed ID: 3510720
[TBL] [Abstract][Full Text] [Related]
4. Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients.
Beurskens FJ; Lindorfer MA; Farooqui M; Beum PV; Engelberts P; Mackus WJ; Parren PW; Wiestner A; Taylor RP
J Immunol; 2012 Apr; 188(7):3532-41. PubMed ID: 22368276
[TBL] [Abstract][Full Text] [Related]
5. Determination of antibody-complement mediated cytotoxicity using ATP release induced by a monoclonal antibody against the Burkitt lymphoma associated globotriaosylceramide antigen.
Wils P; Junqua S; Le Pecq JB
J Immunol Methods; 1986 Mar; 87(2):217-22. PubMed ID: 2419453
[TBL] [Abstract][Full Text] [Related]
6. Effects of human monoclonal antibody 216 on B-progenitor acute lymphoblastic leukemia in vitro.
Bieber MM; Twist CJ; Bhat NM; Teng NN
Pediatr Blood Cancer; 2007 Apr; 48(4):380-6. PubMed ID: 16421902
[TBL] [Abstract][Full Text] [Related]
7. Use of a cocktail of monoclonal antibodies and human complement in selective killing of acute lymphocytic leukemia cells.
Sugita K; Majdic O; Stockinger H; Holter W; Köller U; Peschel C; Knapp W
Int J Cancer; 1986 Mar; 37(3):351-7. PubMed ID: 3456339
[TBL] [Abstract][Full Text] [Related]
8. Restricted expression of an early myeloid and monocytic cell surface antigen defined by monoclonal antibody M195.
Tanimoto M; Scheinberg DA; Cordon-Cardo C; Huie D; Clarkson BD; Old LJ
Leukemia; 1989 May; 3(5):339-48. PubMed ID: 2716349
[TBL] [Abstract][Full Text] [Related]
9. Monoclonal antibody DLC-48: an effective reagent for use in the depletion of malignant lymphoma from human bone marrow.
Winter JN; Marder RJ; Radosevich JA; Epstein AL
Int J Cancer; 1987 Jun; 39(6):670-7. PubMed ID: 3294609
[TBL] [Abstract][Full Text] [Related]
10. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity.
Schmidt-Wolf IG; Negrin RS; Kiem HP; Blume KG; Weissman IL
J Exp Med; 1991 Jul; 174(1):139-49. PubMed ID: 1711560
[TBL] [Abstract][Full Text] [Related]
11. Functional properties of FC-2.15, a monoclonal antibody that mediates human complement cytotoxicity against breast cancer cells.
Ballaré C; Barrio M; Portela P; Mordoh J
Cancer Immunol Immunother; 1995 Jul; 41(1):15-22. PubMed ID: 7641216
[TBL] [Abstract][Full Text] [Related]
12. Binding to CD20 by anti-B1 antibody or F(ab')(2) is sufficient for induction of apoptosis in B-cell lines.
Cardarelli PM; Quinn M; Buckman D; Fang Y; Colcher D; King DJ; Bebbington C; Yarranton G
Cancer Immunol Immunother; 2002 Mar; 51(1):15-24. PubMed ID: 11845256
[TBL] [Abstract][Full Text] [Related]
13. Preparation and characterization of monoclonal antibodies recognizing three distinct differentiation antigens (BL1, BL2, BL3) on human B lymphocytes.
Wang CY; Azzo W; Al-Katib A; Chiorazzi N; Knowles DM
J Immunol; 1984 Aug; 133(2):684-91. PubMed ID: 6429242
[TBL] [Abstract][Full Text] [Related]
14. Induced resistance to ofatumumab-mediated cell clearance mechanisms, including complement-dependent cytotoxicity, in chronic lymphocytic leukemia.
Baig NA; Taylor RP; Lindorfer MA; Church AK; LaPlant BR; Pettinger AM; Shanafelt TD; Nowakowski GS; Zent CS
J Immunol; 2014 Feb; 192(4):1620-9. PubMed ID: 24431228
[TBL] [Abstract][Full Text] [Related]
15. A unique antigen expressed on myeloid cells and acute leukemia blast cells defined by a monoclonal antibody.
Ball ED; Graziano RF; Fanger MW
J Immunol; 1983 Jun; 130(6):2937-41. PubMed ID: 6574189
[TBL] [Abstract][Full Text] [Related]
16. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis.
Golay J; Zaffaroni L; Vaccari T; Lazzari M; Borleri GM; Bernasconi S; Tedesco F; Rambaldi A; Introna M
Blood; 2000 Jun; 95(12):3900-8. PubMed ID: 10845926
[TBL] [Abstract][Full Text] [Related]
17. CD30-specific AB1-AB2-AB3 internal image antibody network: potential use as anti-idiotype vaccine against Hodgkin's lymphoma.
Pohl C; Renner C; Schwonzen M; Schobert I; Liebenberg V; Jung W; Wolf J; Pfreundschuh M; Diehl V
Int J Cancer; 1993 May; 54(3):418-25. PubMed ID: 8389737
[TBL] [Abstract][Full Text] [Related]
18. Enhanced antitumor effects of CD20 over CD19 monoclonal antibodies in a nude mouse xenograft model.
Hooijberg E; van den Berk PC; Sein JJ; Wijdenes J; Hart AA; de Boer RW; Melief CJ; Hekman A
Cancer Res; 1995 Feb; 55(4):840-6. PubMed ID: 7531616
[TBL] [Abstract][Full Text] [Related]
19. Human Lyb-2 homolog CD72 is a marker for progenitor B-cell leukemias.
Schwarting R; Castello R; Moldenhauer G; Pezzutto A; von Hoegen I; Ludwig WD; Parnes JR; Dörken B
Am J Hematol; 1992 Nov; 41(3):151-8. PubMed ID: 1384316
[TBL] [Abstract][Full Text] [Related]
20. Effect of alemtuzumab on neoplastic B cells.
Golay J; Manganini M; Rambaldi A; Introna M
Haematologica; 2004 Dec; 89(12):1476-83. PubMed ID: 15590398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
